A veteran banker and former pharma R&D chief are launching a fund that will buy up some of the nearly 300 listed biotechs that have had disappointing clinical trials, returning cash to shareholders and acquiring any valuable intellectual property.
一位资深银行家与一名前制药公司研发主管正联手推出一只基金，计划收购临床试验表现令人失望的近300家上市生物技术公司中的部分企业，将现金返还给股东，并获取其中有价值的知识产权。
您已阅读9%（334字），剩余91%（3326字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。